353 related articles for article (PubMed ID: 16709521)
1. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.
Cheung WW; Hwang GY; Tse E; Kwong YL
Haematologica; 2006 May; 91(5 Suppl):ECR13. PubMed ID: 16709521
[TBL] [Abstract][Full Text] [Related]
2. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A; Karlsson C; Lundin J
Curr Hematol Malig Rep; 2009 Jan; 4(1):47-53. PubMed ID: 20425438
[TBL] [Abstract][Full Text] [Related]
5. Infectious toxicity using alemtuzumab.
Nosari A; Montillo M; Morra E
Haematologica; 2004 Dec; 89(12):1415-9. PubMed ID: 15590388
[No Abstract] [Full Text] [Related]
6. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?
D'Arena G; Taylor RP; Cascavilla N; Lindorfer MA
Endocr Metab Immune Disord Drug Targets; 2008 Mar; 8(1):62-8. PubMed ID: 18393924
[TBL] [Abstract][Full Text] [Related]
7. Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab.
Gottardo NG; Baker DL; Willis FR
Pediatr Hematol Oncol; 2003; 20(7):557-61. PubMed ID: 12959862
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab for giant cell hepatitis with autoimmune hemolytic anemia.
Rovelli A; Corti P; Beretta C; Bovo G; Conter V; Mieli-Vergani G
J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):596-9. PubMed ID: 18030239
[No Abstract] [Full Text] [Related]
9. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome.
Erdozain JG; Ruiz-Irastorza G; Egurbide MV; Aguirre C
Haematologica; 2004 Sep; 89(9):ECR34. PubMed ID: 15377486
[TBL] [Abstract][Full Text] [Related]
10. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
O'Brien S; Ravandi F; Riehl T; Wierda W; Huang X; Tarrand J; O'Neal B; Kantarjian H; Keating M
Blood; 2008 Feb; 111(4):1816-9. PubMed ID: 18039954
[TBL] [Abstract][Full Text] [Related]
11. Immune hemolytic anemia--selected topics.
Hoffman PC
Hematology Am Soc Hematol Educ Program; 2009; ():80-6. PubMed ID: 20008185
[TBL] [Abstract][Full Text] [Related]
12. [Successful treatment with rituximab in a patient with refractory mixed-type autoimmune hemolytic anemia].
Ono K; Sato T; Iyama S; Tatekoshi A; Hashimoto A; Kamihara Y; Horiguchi H; Kikuchi S; Takada K; Hayashi T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
Rinsho Ketsueki; 2013 Nov; 54(11):2053-5. PubMed ID: 24305538
[TBL] [Abstract][Full Text] [Related]
13. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment.
Barros MM; Blajchman MA; Bordin JO
Transfus Med Rev; 2010 Jul; 24(3):195-210. PubMed ID: 20656187
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC
Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
Nguyen DD; Cao TM; Dugan K; Starcher SA; Fechter RL; Coutre SE
Clin Lymphoma; 2002 Sep; 3(2):105-10. PubMed ID: 12435283
[TBL] [Abstract][Full Text] [Related]
16. [Autoimmune hemolytic anemia: diagnosis and management].
Philippe P
Presse Med; 2007 Dec; 36(12 Pt 3):1959-69. PubMed ID: 17481848
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
Robak T
BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
[TBL] [Abstract][Full Text] [Related]
18. [Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune hemolytic anemia].
Wang L; Xu W; Li JY; Xie XY; Sheng RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):425-8. PubMed ID: 17493362
[TBL] [Abstract][Full Text] [Related]
19. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
[TBL] [Abstract][Full Text] [Related]
20. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.
Elimelakh M; Dayton V; Park KS; Gruessner AC; Sutherland D; Howe RB; Reding MT; Eastlund T; van Burik JA; Singleton TP; Gruessner RW; Key NS
Haematologica; 2007 Aug; 92(8):1029-36. PubMed ID: 17640860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
